» Authors » Laurence C Chen

Laurence C Chen

Explore the profile of Laurence C Chen including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 221
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Lakhani A, Chen X, Chen L, Hong M, Khericha M, Chen Y, et al.
Nat Metab . 2024 Apr; 6(6):1143-1160. PMID: 38658805
Metabolism is an indispensable part of T cell proliferation, activation and exhaustion, yet the metabolism of chimeric antigen receptor (CAR)-T cells remains incompletely understood. CARs are composed of extracellular domains-often...
2.
Lakhani A, Chen X, Chen L, Khericha M, Chen Y, Park J
bioRxiv . 2023 Apr; PMID: 37066394
Metabolism is an indispensable part of T-cell proliferation, activation, and exhaustion, yet the metabolism of chimeric antigen receptor (CAR)-T cells remains incompletely understood. CARs are comprised of extracellular domains that...
3.
Chen X, Chen L, Khericha M, Meng X, Salvestrini E, Shafer A, et al.
Cancer Immunol Res . 2022 Nov; 11(2):150-163. PMID: 36409926
Chimeric antigen receptors (CAR) are fusion proteins whose functional domains are often connected in a plug-and-play manner to generate multiple CAR variants. However, CARs with highly similar sequences can exhibit...
4.
Chen L, Hou A, Chen Y
Med . 2022 May; 2(7):785-787. PMID: 35590214
Although remarkably successful against liquid tumors, chimeric antigen receptor (CAR)-T cell therapy has been stymied by solid tumors, limited by inadequate specificity and poor efficacy. Pairing synthetic Notch (synNotch) receptors...
5.
Hou A, Chen L, Chen Y
Nat Rev Drug Discov . 2021 May; 20(7):531-550. PMID: 33972771
The adoptive transfer of T cells that are engineered to express chimeric antigen receptors (CARs) has shown remarkable success in treating B cell malignancies but only limited efficacy against other...
6.
Chen L, Chen Y
Curr Opin Biotechnol . 2019 Mar; 60:111-118. PMID: 30822698
Adoptive T-cell therapy has shown remarkable clinical efficacy in treating refractory hematological cancers. However, challenges presented by solid tumors impede the applicability of adoptive T-cell therapy to the majority of...